Pulmonary Hypertension - Pipeline Insight, 2025: Unlocking Novel Mechanisms to Address Vascular Remodeling and Right Heart Failure | DelveInsight

Pulmonary Hypertension (PH), a complex and progressive disorder characterized by elevated pulmonary arterial pressure and vascular resistance, often leads to right heart failure and reduced survival if left untreated. While current therapies primarily focus on vasodilation and symptom control, there is a growing demand for innovative treatments that go beyond symptomatic relief to target the root causes of vascular remodeling and right ventricular dysfunction.

DelveInsight's "Pulmonary Hypertension - Pipeline Insight, 2025" explores 50+ emerging therapies under development across various subtypes of PH, including pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and PH associated with interstitial lung disease and left heart disease.

The report highlights novel drug classes such as tyrosine kinase inhibitors (TKIs), soluble guanylate cyclase (sGC) stimulators, Rho kinase (ROCK) inhibitors, anti-inflammatory agents, metabolic modulators, and gene and cell therapies designed to halt disease progression and improve long-term outcomes.

Key pharmaceutical and biotech players like Merck, Altavant Sciences GmbH, Attgeno AB, Bayer, Tenax Therapeutics, and AstraZeneca are spearheading efforts to redefine the therapeutic landscape, with several candidates in Phase II and III trials or in combination regimens to enhance efficacy and broaden clinical utility.

The report also examines novel delivery technologies, including inhaled formulations, implantable pumps, and sustained-release systems, as well as biomarker-driven approaches to guide personalized therapy and early intervention. As the understanding of PH pathophysiology deepens, the focus is shifting toward comprehensive disease-modifying strategies that target endothelial dysfunction, vascular inflammation, and fibrosis.

DelveInsight's analysis underscores a paradigm shift in pulmonary hypertension treatment, moving from symptom-centric care to targeted interventions aimed at preserving cardiac function, improving exercise capacity, and extending survival. With these advances, the PH pipeline is poised to transform patient outcomes and reshape standards of care in the years ahead.

Interested in learning more about the current treatment landscape and the key drivers shaping the pulmonary hypertension pipeline? Click here: https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Pulmonary Hypertension Pipeline Report
• DelveInsight's pulmonary hypertension pipeline analysis depicts a strong space with 45+ active players working to develop 50+ pipeline drugs for pulmonary hypertension treatment.
• The leading pulmonary hypertension companies include Merck & Co. Inc, Altavant Sciences GmbH, Attgeno AB, Bayer, Tenax Therapeutics, Inc, AstraZeneca, OrphAI Therapeutics, Actelion, Geliad Sciences, United Therapeutics, Novartis Pharmaceuticals, and others are evaluating their lead assets to improve the pulmonary hypertension treatment landscape.
• Key pulmonary hypertension pipeline therapies in various stages of development include Sotatercept, Rodatristat ethyl, PDNO, BAY 1237592, TNX-103, AZD3427, LAM-001, Selexipag, MK-5475, Ambrisentan, Inhaled Treprostinil, LTP001, and others.
• In May 2025, Liquidia Corporation (NASDAQ: LQDA) announced FDA approval of YUTREPIATM (treprostinil) inhalation powder to improve exercise ability in adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD).
• In March 2025, SCIENTURE HOLDINGS, INC. announced it completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of ArbliTM (losartan potassium) Oral Suspension. The company also temporarily suspended further ELOC draws for the next 30 trading days or until its stock reaches $10 per share, whichever comes first.

Request a sample and discover the recent breakthroughs happening in the pulmonary hypertension pipeline landscape at https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pulmonary Hypertension Overview
Pulmonary Hypertension (PH) is a progressive and potentially life-threatening condition characterized by elevated blood pressure in the arteries of the lungs. This increase in pressure forces the right side of the heart to work harder, eventually leading to right heart failure if untreated. PH is classified into five groups based on underlying causes, including pulmonary arterial hypertension (PAH), PH due to left heart disease, lung diseases, chronic thromboembolic pulmonary hypertension (CTEPH), and multifactorial mechanisms. Common symptoms, such as shortness of breath, fatigue, chest pain, and fainting, are often non-specific, which delays diagnosis. A combination of echocardiography, right heart catheterization, imagingg, and blood tests is used to confirm and classify the disease.

Current treatments focus on improving symptoms, slowing progression, and enhancing quality of life. These include vasodilators (like endothelin receptor antagonists and PDE5 inhibitors), anticoagulants, oxygen therapy, and in some cases, surgical interventions such as pulmonary thromboendarterectomy or lung transplantation. However, there remains a high unmet need, especially for therapies that address the underlying vascular remodeling and inflammation. The treatment landscape is rapidly evolving, with several disease-modifying and personalized therapies in development. Innovations in gene therapy, cell-based approaches, and advanced drug delivery systems are poised to reshape the future of pulmonary hypertension care.

Find out more about pulmonary hypertension medication at https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pulmonary Hypertension Treatment Analysis: Drug Profile
Seralutinib: GB002, Inc.
Seralutinib is an investigational, inhaled small molecule that targets multiple key receptors implicated in the pathogenesis of pulmonary hypertension, including platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and the mast/stem cell growth factor receptor kit (c-KIT). Designed for targeted delivery to the lungs via a dry powder inhaler, Seralutinib aims to directly address disease mechanisms at the site of action. The drug is currently being evaluated in a Phase III clinical trial for pulmonary arterial hypertension (PAH) and has received Orphan Drug Designation in the US, Europe, and Japan.

TNX-103: Tenax Therapeutics, Inc.
TNX-103 is an oral formulation of levosimendan, a unique potassium ATP channel opener and calcium sensitizer with multiple cardiovascular effects. It is being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)-a condition with no currently approved therapies. In the Phase II HELP study, IV levosimendan significantly improved central and pulmonary venous dilation, translating to enhanced exercise capacity. These findings support the ongoing LEVEL Phase III trial. TNX-103 represents a potentially groundbreaking therapy addressing a serious unmet need in PH-HFpEF.

TX000045: Tectonic Therapeutic
TX45 is a novel Fc-relaxin fusion protein engineered with improved pharmacokinetics and stability, designed to activate RXFP1, the G-protein-coupled receptor for the hormone relaxin. Relaxin naturally functions as a pulmonary and systemic vasodilator with additional anti-fibrotic and anti-inflammatory properties. It is physiologically upregulated during pregnancy, aiding cardiovascular adaptation and tissue remodeling. TX45 leverages these mechanisms to target pulmonary hypertension and is currently in Phase II clinical development.

LAM-001: OrphAI Therapeutics
LAM-001 is a dry powder inhaled formulation of sirolimus (rapamycin), developed to provide targeted pulmonary delivery while minimizing systemic exposure and associated toxicity seen with oral administration. Preclinical and early clinical studies have supported its favorable safety profile. LAM-001 is being evaluated in Phase II trials for pulmonary hypertension, with the aim of offering a safer and more effective treatment option for this chronic lung disease.

Learn more about the novel and emerging pulmonary hypertension pipeline therapies at https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pulmonary Hypertension Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Pulmonary Hypertension Pipeline Report
• Coverage: Global
• Key Pulmonary Hypertension Companies: Merck & Co. Inc, Altavant Sciences GmbH, Attgeno AB, Bayer, Tenax Therapeutics, Inc, AstraZeneca, OrphAI Therapeutics, Actelion, Geliad Sciences, United Therapeutics, Novartis Pharmaceuticals, and others.
• Key Pulmonary Hypertension Pipeline Therapies: Sotatercept, Rodatristat ethyl, PDNO, BAY 1237592, TNX-103, AZD3427, LAM-001, Selexipag, MK-5475, Ambrisentan, Inhaled Treprostinil, LTP001, and others.

To dive deep into rich insights for drugs used for pulmonary hypertension treatment, visit: https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pulmonary Hypertension Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pulmonary Hypertension Pipeline Therapeutics
6. Pulmonary Hypertension Pipeline: Late-Stage Products (Phase III)
7. Pulmonary Hypertension Pipeline: Mid-Stage Products (Phase II)
8. Pulmonary Hypertension Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.